Markers in iPSC quality control – a new approach to enhance standardization
“Machine learning is an attractive tool to streamline processes”
IUF / Jochen Dobner
While quality controls for iPSCs are essential, they are not yet fully standardized. These quality controls include the assessment of morphology, nuclear and mitochondrial genome integrity, and pluripotency, i.e., their capability to differentiate into the three primary germ layers endoderm, ectoderm, and mesoderm. Thus, there is a pressing need for testing methods that are easy, fast, and cost-effective. In former studies the lab of Dr. Andrea Rossi at the IUF – Leibniz Research Institute for Environmental Medicine already looked into mitochondrial genome integrity. A study recently published in Nature Communications by Dobner et al. focuses on pluripotency. The authors used long-read nanopore transcriptome sequencing to discover 172 genes linked to cell states not covered by current guidelines. They validated 12 genes by qPCR (quantitative polymerase chain reaction) as unique markers for specific cell fates: undifferentiated pluripotent iPSCs (CNMD, NANOG, SPP1), endoderm (CER1, EOMES, GATA6), mesoderm (APLNR, HAND1, HOXB7), and ectoderm (HES5, PAMR1, PAX6). Based on these selected genes, they developed a machine learning-based scoring system, “hiPSCore”, which was trained on 15 iPSC lines and validated on additional 10 iPSC lines. The hiPSCore accurately classifies pluripotent and differentiated cells and predicts their potential to become specialized 2D cells and 3D organoids.
“We always strive to improve the methods which we are using”, explains Dr. Andrea Rossi, group leader at the IUF, the approach of the study. “We plan to further develop quality controls for standardized use of iPSCs within the next years.” Dr. Jochen Dobner, first author of the study adds: “Machine learning is an attractive tool to streamline processes. Our developed hiPSCore improves iPSC testing by reducing time, subjectivity, and resource use, thus enhancing iPSC quality for scientific and medical applications.”
Original publication
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.